---
title: "VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296779574.md"
description: "VERAXA Biotech and Secarna Pharmaceuticals have achieved a significant research milestone in their collaboration on Antibody Oligonucleotide Conjugates (AOC). This breakthrough marks progress in developing innovative therapies, leveraging combined expertise to advance biotechnology. The partnership aims to revolutionize medical treatments through cutting-edge technology, with promising results indicating a bright future for AOC research."
datetime: "2026-08-24T11:02:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296779574.md)
  - [en](https://longbridge.com/en/news/296779574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296779574.md)
generator: "portal-rs"
---

# VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

In a significant development, VERAXA Biotech and Secarna Pharmaceuticals have reached a research milestone in their collaboration focused on Antibody Oligonucleotide Conjugates (AOC). The alliance between the two companies has successfully achieved a key milestone, marking progress in the development of innovative therapies. VERAXA Biotech and Secarna Pharmaceuticals are paving the way for advancements in the field of biotechnology by combining their expertise. This breakthrough underscores their commitment to revolutionizing treatments through cutting-edge technologies. The collaboration has the potential to bring about transformative outcomes in the medical landscape, with promising results indicating a bright future for AOC research. Stay tuned for further updates on this groundbreaking partnership.

### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)

## Related News & Research

- [Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650](https://longbridge.com/en/news/297556855.md)
- [Veraxa Biotech reports positive in vitro proof-of-concept for antibody-oligonucleotide conjugate candidate with Secarna](https://longbridge.com/en/news/296781575.md)
- [Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by Van ECK Associates Corp](https://longbridge.com/en/news/297757657.md)
- [ExpreS2ion Biotech to Attend BIO Hong Kong Biotech Conference and Exhibition](https://longbridge.com/en/news/297481566.md)
- [Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs](https://longbridge.com/en/news/297679815.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**